This website is intended for healthcare professionals only
Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic

Comprehensive Anatomical Render Of Breast Cancer In A Human Female
8 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Saumya Easaw, Antoinette R Tan, Arielle L Heeke

Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA […]

touchREVIEWS in Oncology & Haematology. 2026;22(2):1–4:Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Search Results

1 Result Found for “<em id="05e5112f-2725-428c-b874-042791d2a69c">HER2</em>-mutated non-small cell lung cancer”

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
3d medical illustration of lung cancer
Mark CompleteCompleted
BookmarkBookmarked

Targeting HER2 in advanced non-small cell lung cancer: The emerging role of zongertinib

Christopher R Pallas, Daniel R Carrizosa, Kathryn F Mileham

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...

touchREVIEWS in Oncology & Haematology. 2026;22(1):21–28

Latest articles videos and clinical updates - straight to your inbox

Close Popup